Detalhe da pesquisa
1.
Recent advances in immune checkpoint inhibitor-induced type 1 diabetes mellitus.
Int Immunopharmacol
; 122: 110414, 2023 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-37390646
2.
Changes of tumor microenvironment in non-small cell lung cancer after TKI treatments.
Front Immunol
; 14: 1094764, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36949948
3.
Recent Advances in the Management of Adverse Events Associated with Lorlatinib.
Onco Targets Ther
; 16: 731-738, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37694103
4.
Advances in pharmacokinetics and pharmacodynamics of PD-1/PD-L1 inhibitors.
Int Immunopharmacol
; 115: 109638, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36587500
5.
Recent Advancements of Monotherapy, Combination, and Sequential Treatment of EGFR/ALK-TKIs and ICIs in Non-Small Cell Lung Cancer.
Front Pharmacol
; 13: 905947, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35734411
6.
Two new triterpenoid glycosides from leaves of Cyclocarya paliurus.
Nat Prod Res
; 36(20): 5277-5282, 2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-34034582
7.
Single-Cell Profiling to Explore Immunological Heterogeneity of Tumor Microenvironment in Breast Cancer.
Front Immunol
; 12: 643692, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-33717201
8.
Immunomodulatory Therapies for Renal Cell Carcinoma.
Protein Pept Lett
; 25(6): 534-547, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29848257
9.
Therapeutic Drug Monitoring of Targeted Therapy in Metastatic Renal Cell Carcinoma.
Protein Pept Lett
; 25(6): 528-533, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29848258